Theralase®'s latest preclinical research supports the premise that both the safety and efficacy of immunotherapy drugs can be substantially increased in the destruction of cancer by allowing cancer cells to be more readily identified by the immune system.
The immune system defends and protects our bodies from infection and disease via specialized cells and chemical signal processes that work together to find and fight pathogens such as: viruses, bacteria, and abnormal cells that cause disease, such as cancer. Cancer cells have antigens on their surface that trigger the immune system to find and destroy them, but some antigens can allow them to hide from the immune system surveillance.
Examples of immunotherapy drugs, include: Chimeric Antigen Receptor ("CAR") T-cell therapy, cancer vaccines and immune checkpoint inhibitors, such as monoclonal antibodies.
It is therefore desirable to provide additional therapies to assist immunotherapy drugs to destroy these cancer cells for a whole-body approach in the destruction of cancer.
Theralase(R) Files US Patent for Enhanced Immunotherapy - The Globe and Mail